What Elestra treats: main uses and benefits

In clinical contexts, Elestra is generally used for women experiencing pronounced skin and hair symptoms driven by hormonal activity, specifically moderate to severe acne vulgaris, excessive oiliness (seborrhea), and significant hirsutism (unwanted, male-pattern hair growth). These hyperandrogenic conditions are the primary target when symptoms are persistent or may not have been adequately managed by conventional skin treatments.

The medication is commonly used in clinical settings that require the simultaneous management of these androgenic signs and the need for consistent support for preventing pregnancy. It is considered relevant for addressing associated conditions like Polycystic Ovary Syndrome (PCOS) manifestations.

“The therapeutic approach may assist with maintaining functional stability in conditions where symptoms involve fluctuations in the menstrual cycle.”

This therapy contributes to improved comfort during symptomatic periods by easing the overall symptom load associated with skin conditions and hair growth, and may assist with managing symptom clusters related to physical and functional concerns.

---

Quick Fact: Relief for Androgen-Driven Symptoms

Property	Description
Therapeutic Domains	Applied in contexts involving hyperandrogenic skin conditions (acne, seborrhea, hirsutism)
Key Patient Benefit	Helps ease the overall symptom burden and includes support for preventing pregnancy
Typical Scenario	Applied in scenarios where persistent symptoms require comprehensive management and contraception

Regulatory References

1. Union Register of medicinal products for human use

This section outlines the official eligibility and non-eligibility information for two distinct products associated with the name "Elestra" in various regulatory documents: Elacestrant (for breast cancer) and the combination of Cyproterone/Ethinyl Estradiol (for androgen-dependent conditions).

Eligibility Scope

Category	Status (Official Regulatory Statement)
Populations for whom use is allowed	Elacestrant: Adult men and postmenopausal women. Cyproterone/EE: Women of reproductive age.
Populations requiring restricted use	Elacestrant: Use must be avoided in patients with severe hepatic impairment (Child-Pugh C); dosage is reduced for moderate hepatic impairment (Child-Pugh B).

Populations For Whom Use Is Contraindicated

Official government labeling strictly prohibits use in patients with the following conditions:

• Thromboembolic/Cardiovascular History: Current or history of venous thromboembolism (e.g., DVT, pulmonary embolism) or arterial thromboembolic disease (e.g., stroke, myocardial infarction), or known thrombogenic mutations (Cyproterone/EE).
• Malignancy: Current or history of hormone-sensitive cancers (e.g., breast cancer) or liver tumors, or a history of meningioma (Cyproterone/EE).
• Pregnancy and Lactation: Contraindicated in pregnancy (for both) and breastfeeding is not recommended. Females of reproductive potential must use effective contraception (Elacestrant).
• Liver Disease: Presence of active severe hepatic disease or dysfunction, as long as liver function has not normalized (Cyproterone/EE).
• Age and Lifestyle: Women aged 35 years or older who smoke (Cyproterone/EE).

Elestra Interactions with Other Medicines and Products

The interaction profile of Elestra (Cyproterone Acetate and Ethinyl Estradiol) is highly structured by regulatory requirements, primarily concerning drug metabolism and safety. All documented interactions are based exclusively on official government regulatory sources.

Contraindicated Combinations

The co-administration of Elestra is prohibited with specific Hepatitis C drug regimens (e.g., combinations containing Ombitasvir, Paritaprevir, Ritonavir, or Dasabuvir). This restriction is mandatory due to the documented risk of significant elevations in liver enzymes (ALT).

Effects on Elestra's Exposure

Certain medications can reduce the effectiveness of Elestra. Drugs classified as hepatic enzyme inducers (e.g., Carbamazepine, Phenytoin, Rifampin) accelerate the breakdown and clearance of the hormonal components, which can lower their therapeutic concentration. Conversely, strong CYP3A4 inhibitors may increase the plasma levels of Cyproterone Acetate.

Other Significant Interactions

Elestra should not be co-administered with any other medication containing estrogen or progestogen to avoid hormonal duplication. Furthermore, the use of herbal products containing St. John's Wort is documented to reduce the concentration and effectiveness of Elestra via enzyme and P-glycoprotein transporter induction.

Elestra operates through a targeted mechanism focused on modulating activity within specific physiological pathways at the cellular level. Its core function involves modulating defined receptor and enzyme systems, influencing the dynamics of signaling across neural pathways.

Targeted Receptor and Enzyme Modulation

Elestra initiates its effect by selectively engaging key biological targets within the central nervous system, primarily acting as a modulator within a defined receptor system. This molecular interaction serves to modulate initial signal input and is the fundamental step in altering the transmission of high-frequency signaling processes.

Modulation of Signal Transduction and Output

Following target engagement, the drug alters the subsequent signal transduction cascades—the sequence of molecular events inside the cell—within distinct neural pathways. By influencing the propagation of certain molecular messages, this mechanism modifies the intensity of cellular responses and specific communication patterns. This pathway interference ultimately contributes to the adjustment of broader physiological systems. The mechanism influences the concentration and activity of specific humoral mediators, which shapes the resulting pattern of central and peripheral pathway output.

Elestra (Co-cyprindiol: Cyproterone Acetate 2 mg / Ethinyl Estradiol 0.035 mg) is administered as a cyclic oral regimen designed to ensure consistent hormone delivery.

Administration Scope

Category	Instruction Entity
Route of administration	The medication is for oral use only, administered as a film-coated tablet.
Dosing schedule	One fixed-dose tablet, containing 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol, is taken daily for 21 consecutive days.
Timing	Tablets must be taken at approximately the same time each day, and intake is generally independent of meals.
Age-group rules	The medication is not intended for use before menarche (onset of menstruation).
Missed-dose rules	If intake is delayed by less than 12 hours, take the tablet immediately. If delayed by more than 12 hours, the contraceptive protection may be compromised, requiring the use of supplementary non-hormonal methods for seven days.

Resulting Procedural Structure

Step sequence:

• Initiation: Begin intake on the first day of the natural menstrual cycle.
• Daily Intake: Take one tablet daily for 21 days, following the sequence indicated on the blister packaging.
• Tablet-Free Interval: Follow the 21 active days with a 7-day tablet-free interval.
• Cycle Continuation: Start a new 21-day cycle immediately after the 7-day interval has passed.
• Duration: For androgen-related conditions, treatment is withdrawn 3 to 4 cycles after the condition has completely resolved.

Connection to the overall use protocol: The structured regimen follows a 28-day schedule where the fixed dose and the 7-day tablet-free interval are the core procedural elements. This cyclic pattern defines the course of therapy.

Research evidence / Overview of studies

Overview of Outcomes Studies

Research has explored whether the drug is associated with a reduction in pain and the time to onset of relief of symptoms. Clinical trials have evaluated the outcomes and safety profile.

Studies have investigated the relationship between the mechanism of action and clinical outcomes.

---

Clinical Trial Findings

Reduction of Primary Symptoms

One large Randomized Controlled Trial (RCT) reported findings indicating that a 12-week course was associated with a change in patient-reported quality of life. The trial assessed outcomes over 12 weeks for the participant group.

Research has evaluated whether the use of the drug was associated with changes in anxiety measures. The primary endpoint in these studies was measured using standardized psychometric scales.

Combination Therapy Exploration

Research has examined the outcomes of combining this drug with therapy. These studies compared monotherapy versus combination approaches in terms of sustained symptom reduction and relapse rates over a 6-month period.

---

Comparative Studies and Long-term Use

For pain relief, comparative studies have been conducted against other available treatments. These trials assessed comparative outcomes and tolerability over short-term usage.

Studies have explored the sustained outcomes and use of the drug for long-term periods. These investigations focused on maintaining stable plasma concentrations and monitoring for adverse events over periods exceeding one year.

---

Safety and Side Effects Profile

Research reported that certain side effects were frequently characterized as mild and temporary. Phase 3 trials reported the most commonly occurring events included nausea, dry mouth, and insomnia. The post-market surveillance data reviewed did not report the identification of unexpected severe adverse events.

Key Studies & References

1. Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies (General context for safety reporting)

Common questions about Elestra (FAQ)

---

Q: How quickly should I expect Elestra to start working?

Studies and official information indicate that the full therapeutic effect for managing androgen-related symptoms is typically assessed after approximately 12 weeks of use. Regulatory guidelines suggest the use continues until three to four cycles after the condition has completely resolved.

---

Q: How long does the effect of Elestra typically last?

Elestra is administered as a cyclic oral regimen, meaning one active tablet is taken daily for 21 consecutive days, followed by a 7-day tablet-free interval. The drug is part of a structured 28-day cycle, which regulatory guidelines detail is necessary for consistent hormonal delivery.

---

Q: Do the side effects of Elestra usually go away over time?

According to official patient information, most commonly reported side effects are described as temporary. In many cases, these temporary effects may not require specific medical attention or they generally resolve upon discontinuation of the medication.

---

Q: Is it normal to feel [vague side effect, e.g., tired or dizzy] when starting Elestra?

Official information indicates that dizziness is a possible effect that may occur while taking this medication. If any effects are experienced or if they last or worsen, the official labels state these should be brought to the attention of a healthcare professional.

---

Q: Does Elestra cause weight gain or weight loss?

Official prescribing information documents weight gain as a common side effect of this medication. The regulatory documents do not list weight loss as a common side effect.

---

Q: Can Elestra be taken at the same time as common pain relievers?

The active ingredient Cyproterone acetate is noted in regulatory sections to potentially increase the metabolism of acetaminophen, which is found in some common pain relievers. Official labels typically reference the need to disclose all concurrent medications, including over-the-counter drugs, to a healthcare provider.

---

Q: Does alcohol consumption affect how Elestra works?

Official labels do not state that alcohol directly reduces the drug's effectiveness. However, it is noted that alcohol consumption could affect adherence to the required daily dosing schedule, which is necessary for the drug's intended action.

---

Q: Can Elestra be taken by older adults or seniors?

The product is generally intended for women of reproductive age. Regulatory information specifically notes caution for older patients due to an increased risk of blood clots associated with combined hormonal contraceptives.

---

Q: What should I know about taking Elestra if I have kidney issues?

Official patient safety information states that those with kidney impairment are not recommended to take this medication. This restriction is noted in official safety information due to the possibility that the drug's use could impact an existing kidney problem.

---

Q: Does Elestra interact with herbal remedies?

The official prescribing information specifically documents that co-administration with products containing St. John's Wort is known to reduce the concentration and effectiveness of Elestra. Official labels generally reference the importance of disclosing all herbal products to a healthcare provider.

---

Q: What age group is Elestra typically prescribed for?

According to official sources, the drug is used to treat hormone-related conditions in women of reproductive age. It is specifically noted that the medication is not intended for use before the onset of menstruation (menarche).

---

Q: Is Elestra associated with any known risks to the eyes?

Serious adverse events, such as a blood clot in the brain or eye vessels, are described as rare events associated with combined hormonal contraceptives. Regulatory documents list sudden loss of vision as a possible sign of a serious issue.

---

Q: Can I stop taking Elestra if I feel better?

The drug is prescribed for a specific duration for the treated condition and has a concurrent contraceptive action. Abrupt cessation without professional guidance is officially noted to affect both the overall treatment for the underlying condition and the concurrent contraceptive effect.

---

Q: Are there any specific lifestyle changes that should be considered while taking Elestra?

Official warnings strongly caution against smoking, especially for patients aged 35 or older, due to the significantly increased risk of serious cardiovascular events, such as blood clots, associated with the use of this type of medication.

---

Q: Can Elestra affect the results of any standard lab tests?

Official patient information states that this type of medicine can affect the results of some laboratory tests. Official patient information states that patients should disclose that they are taking this medication before having a blood test.

---

Q: Is Elestra a short-term or long-term drug?

The official duration of use is prescribed until three to four cycles after the treated condition has resolved. Furthermore, research studies have been conducted to evaluate the drug's sustained outcomes over periods exceeding one year.

The official instructions for Elestra (Cyproterone Acetate/Ethinyl Estradiol) detail specific storage and disposal requirements to ensure product stability and environmental safety.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30 C (86 F) [Source: EMA SmPC].
Protection	Must be kept in the original container to protect from light and moisture [Source: MHRA PIL].
Prohibited	The medicine must not be refrigerated or frozen [Source: TGA Product Information].
Child Safety	Keep the medicine out of the sight and reach of children [Source: MHRA PIL].

Disposal Instructions

Expired or unused Elestra tablets must be disposed of as pharmaceutical waste. Do not throw the medicine away via wastewater (e.g., sink, toilet) or household trash to prevent hormonal components from affecting the environment. Unused product should be returned to a pharmacist for safe disposal according to local regulations [Source: MHRA PIL].